Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-17
2011-05-17
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S023500, C435S091200, C435S091210
Reexamination Certificate
active
07943310
ABSTRACT:
A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.
REFERENCES:
patent: 5328470 (1994-07-01), Nabel et al.
patent: 5843767 (1998-12-01), Beattie
patent: 2002/0006622 (2002-01-01), Bradley et al.
patent: 2006/0134663 (2006-06-01), Harkin et al.
patent: 2008/0293582 (2008-11-01), Li et al.
patent: 2010/0069256 (2010-03-01), Baribaud et al.
patent: WO 93/18186 (1993-09-01), None
patent: WO 01/94630 (2001-12-01), None
patent: WO2004/002417 (2004-01-01), None
patent: WO 2004/112589 (2004-12-01), None
patent: WO 2008/028044 (2008-03-01), None
Liu et al. Clinical Immunology. 2004. 112: 225-230.
Coleman et al. Drug Discovery Today. 2003. 8: 233-235.
Saetre et al. Molecular Brain Research. 2004. 126: 198-206.
Costello et al. PLoS Med. Aug. 23, 2005. 2(8): e199.
Singh et al. Proceedings of the New Zealand Society of Animal Production. 2004. 64: 8-10.
Csillag et al. Scandinavian Journal of Gastroenterology. 42(7): 834-840.
Burczynski et al. Journal of Molecular Diagnostics. Feb. 2006. 8(1): 51-61 and Supplement Table S1.
Affymetrix (Design and Performance of the GeneChip Human Genome U133 Plus 2.0 and Human Genome U133A 2.0 array. 2003-2004, available via url: <affymetrix.com>.
Genecard for IL-24, available via url: <genecards.org> , printed Jul. 29, 2009.
Genecard for OSM, available via url: <genecards.org> , printed Jul. 29, 2009.
Genecard for PTGES, available via url: <genecards.org> , printed Jul. 29, 2009.
Genecard for protocadherin 17, available via url: <genecards.org> , printed Jul. 29, 2009.
GeneCard for CPA6, (available via url: <genecards.org> , printed Jul. 29, 2009.
Rutgeerts et al. New England Journal of Medicine. 2005. 353: 2462-2476.
Al-Sadi, et al., “Mechanism of IL-1 {beta}-induced increase in intestinal epithelial tight junction permeability,” J. Immunol. 2008:180:5653-5661.
Amasheh, et al., “Cytokine-dependent transcriptional down-regulation of epithelial sodium channel in ulcerative colitis,” Gastroenterology, 2004: 126:1711-1720.
Balding, et al., “Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms,” Med. Inflam. 2004:13:181-187.
Banks, et al., “Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease,” J. Pathol. 2003:199:28-35.
Ben-Baruch, et al., “Signals and receptors involved in recruitment of inflammatory cells,” J. Biol. Chem. 1995: 270:11703-11706.
Bermejo, et al., “Adaptive softk-nearest-neighbor classifiers,” Pattern Recog. 2000: 33:1999-2005.
Braegger, et al., “Tumour necrosis factor alpha in stool as a marker of intestinal inflammation,” Lancet 1992: 339:389.
Brun, et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” Am. J. Physiol. Gastrointest. Liver Physiol. 2007:292:G518-G525.
Burdzynski, et al., “Molecular Classification of Crohn's Disease and Ulcerative Colitis Patients Using Transcriptional Profiles in Peripheral Blood Mononuclear Cells,” Journal of Molecular Diagnostics, 2006: 8(1): 51-61.
Chen, et al., “Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo,” Proc. Natl. Acad. Sci. USA. 1994: 91: 3054-3057.
Colliver, et al., “Molecular profiling of ulcerative colitis-associated neoplastic progression,” Experimental and Molecular Pathology, 2005: 80(1): 1-10.
Comelli, et al., “Biomarkers of human gastrointestinal tract regions,” Mamm. Genome, 2009: 20: 516-527.
Craig, et al., “Removal of repetitive sequences from FISH probes using PCT-assisted affinity chromatography,” Hum. Genet. 2007: 100:472-476.
Cruikshank, et al., “A Lipidated Anti-Tat Antibody Enters Living Cells and Blocks HIV-1 Viral Replica,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, 1997: 14(3): 193-203.
Frolova, et al., “Expression of Toll-like Receptor 2 (TLR2), TLR4, and CD14 in Biopsy Samples of Patients With Inflammatory Bowel Diseases: Upregulated Expression of TLR2 in Terminal Ileum of Patients With Ulcerative Colitis,” J. Histochem. Cytochem. 2008:56:267-274.
Geboes et al., “A reproducible grading scale for histological assessment of inflammation in ulcerative colitis,” Gut 2000:47:404-409.
Greenberg, et al., “Phagocytosis and innate immunity,” Curr. Opin. Immunol. 2002:14:136-145.
Guo, et al., “Role of C5a—C5ar interaction in sepsis,” Shock 2004:21:1-7.
Hanauer, et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002: 359:1541-1549.
Hart, et al., “Characteristics of Intestinal Dendritic Cells in Inflammatory Bowel Diseases,” Gastroenterology 2005:129:50-65.
Hayashi, et al., “Toll-like receptors stimulate human neutrophil function,” Blood 2003:102:2660-2669.
Hughes, et al., “Expression Profiling of Wnt Family of Genes in Normal and Inflammatory Bowel Disease Primary Human Intestinal Myofibroblasts and Normal Human Colonic Crypt Eipthelial Cells,” Inflammatory Bowel Disease 2010:1-8.
Izzo, et al., “Interleukin-8 and neutrophils markers in colonic mucosa from patients with ulcerative colitis,” Am. J. Gastroenterol .1992:87:1447-1452.
Klein, et al., “A polymorphism in the IL11 gene is associated with ulcerative colitis,” Genes Immun. 2002:3:494-496.
Kusam, et al., “Inhibition of Th2 differentiation and GATA-3 expression by BCL-6,” J. Immunol. 2003:170:2435-41.
Leeb, et al., “Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase,” Gastroenterology, 2003: 125:1341-1354.
Linder, et al., “Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency,” Clin. Chem, 1997: 43(2): 254-266.
Liu, et al., “Regulation of leukocyte transmigration: cell surface interactions and signaling events,” J. Immunol. 2004:172:7-13.
Melgar, et al., “Over-expression of interleukin 10 in mucosal T cells of patients with active ulcerative colitis,” Clin. Exp. Immunol. 2003: 134:127-137.
Mesko, et al., “Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets,” BMC Medical Genomics 3: 1-15(2010).
Mizoguchi, et al., “Role of tumor necrosis factor receptor 2 (TNFR2) in colonic epithelial hyperplasia and chronic intestinal inflammation in mice,” Gastroenterology, 2002: 122:134-144.
Murch, et al., “Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease,” Gut 1991: 32:913-917.
Murch, et al., “Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease,” Gut 1993: 34:1705-1709.
Noble, et al., “Regional variation in gene expression in the healthy colon is dysregulated in ulcerative colitis,” Gut 57(10): 1398-1405 (2008).
Okahara, et al., “Inflammatory gene signature in ulcerative colitis with cDNA macroarray analysis,” Aliment Pharmacol. Ther. 2005: 21:1091-1097.
Olsen, et al., “Diagnosis of Ulcerative Colitis Before Onset of Inflammation of Multivariate Modeling of Genome-wide Gene Expression Data,” Inflammatory Bowel Disease, 2009: 15: 1032-1038.
Pender, et al., “Matrix metalloproteinases and the gut—new roles for old enzymes”—Curr. Opin. P
Li Xilin
Song Xiao-yu
Centocor Ortho Biotech Inc.
Dichter Eric
Myers Carla
LandOfFree
Methods for assessing response to therapy in subjects having... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for assessing response to therapy in subjects having..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for assessing response to therapy in subjects having... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2661890